Lemon Bio raises $30M Series B led by China Securities Capital

What's the deal? Guangzhou-based Lemon BioDealroom has a profile for this one. Try Dealroom → has closed a Series B round of nearly 200 million CNY (roughly $30 million). China Securities Capital led the round, with Yufu Capital, Hubei Agricultural Development, and Yuncheng Industrial Investment participating.

What's the endgame? Lemon Bio plans to use the funds to expand production capacity nationwide and step up research and development spending. It also aims to deepen supply-chain coordination, accelerate its international expansion, and refine its governance and capital structure.

The signal: The round's investor lineup is its most notable feature, pairing a state-backed securities house with regional industrial and agricultural investors — a mix that signals growing institutional appetite for China's biotech sector.

Image credit: Generated with Gemini